Drugs / Pregabalin naproxencarbil
Pregabalin naproxencarbil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06017999 | Aug 2023 → Aug 2024 | — | Xgene Pharmaceutical Group | Completed | Met primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pregabalin naproxencarbil | “Pregabalin naproxencarbil in acute post-bunionectomy pain: a randomized clinical trial.” PMID 41737923 ↗ Jan 2026 |
| Known as | PNC | “The study aimed to assess pregabalin naproxencarbil (PNC), a new chemical entity targeting both nociceptive and neuropathic pain pathways, for the management of acute pain.” PMID 41737923 ↗ Jan 2026 |
| Known as | Pregabalina naproxencarbilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068028 ↗ |
| Known as | Pregabaline naproxencarbil | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068028 ↗ |
| Known as | XG005 | “This study will evaluate the safety, efficacy, and PK of low dose (750 mg) and high-dose (1250 mg) XG005 oral tablets compared with placebo” NCT06017999 ↗ |
| Modality | Small molecule | — CHEMBL6068028 ↗ |
| Route | Oral | “XG005 oral tablets” NCT06017999 ↗ |